Arkolith/Insider Trading/ENTX/Form 4/A

Yaacov-Garbeli Dana

Chief Financial OfficerEntera Bio Ltd. (ENTX) · full profile →Form 4/A · filed Aug 2, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Apr 19, 2024Grant(A)30K—$087K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Apr 19, 2024Grant(A)130K—$0130K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4/A filing (accession 0001178913-24-002392) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4/A XML